What legal protections do pharmaceutical companies have against lawsuits from COVID vaccine injuries, and what recourse do injured individuals have?

Pharmaceutical companies are protected from COVID vaccine injury lawsuits through the PREP Act, which provides blanket immunity under Emergency Use Authorization (EUA). This protection extends beyond COVID vaccines to other treatments like remdesivir and monkeypox vaccines, leaving injured individuals with no legal recourse against manufacturers. Currently, over 100 legal challenges to the PREP Act have failed, making Brianne Dressen's AstraZeneca case potentially the first to succeed in challenging this protection. Injured individuals are essentially on their own, with no established support programs or dedicated research into addressing vaccine-related harms. The situation highlights a significant gap in accountability, where those harmed by vaccines have limited options and must often rely on informal networks of other injured individuals to find information and support, creating an urgent need for legal and policy reforms.